有认知障碍和无认知障碍帕金森病患者食欲控制的代谢生物标志物

IF 2.9 Q3 NUTRITION & DIETETICS

Clinical nutrition ESPEN Pub Date : 2024-11-02 DOI:10.1016/j.clnesp.2024.10.167

Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn

{"title":"有认知障碍和无认知障碍帕金森病患者食欲控制的代谢生物标志物","authors":"Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn","doi":"10.1016/j.clnesp.2024.10.167","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.</div></div><div><h3>Methods</h3><div>Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m<sup>2</sup>), nineteen PD patients without CI (72.5 y, 25.1 kg/m<sup>2</sup>) and sixteen PD patients with CI (74.3 y, 24.0 kg/m<sup>2</sup>). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat <em>ad libitum</em> with the aim to evaluate links between metabolic biomarkers and control of energy intake.</div></div><div><h3>Results</h3><div>PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h<sup>−1</sup>, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of <em>ad libitum</em> energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).</div></div><div><h3>Conclusions</h3><div>PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.</div></div>","PeriodicalId":10352,"journal":{"name":"Clinical nutrition ESPEN","volume":"64 ","pages":"Pages 425-434"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic biomarkers of appetite control in Parkinson's disease patients with and without cognitive impairment\",\"authors\":\"Mario Siervo , Fionnuala Johnston , Emily Calton , Anthony James , Blossom C.M. Stephan , Amanda K.E. Hornsby , Jeffrey S. Davies , David Burn\",\"doi\":\"10.1016/j.clnesp.2024.10.167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.</div></div><div><h3>Methods</h3><div>Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m<sup>2</sup>), nineteen PD patients without CI (72.5 y, 25.1 kg/m<sup>2</sup>) and sixteen PD patients with CI (74.3 y, 24.0 kg/m<sup>2</sup>). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat <em>ad libitum</em> with the aim to evaluate links between metabolic biomarkers and control of energy intake.</div></div><div><h3>Results</h3><div>PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h<sup>−1</sup>, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of <em>ad libitum</em> energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).</div></div><div><h3>Conclusions</h3><div>PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.</div></div>\",\"PeriodicalId\":10352,\"journal\":{\"name\":\"Clinical nutrition ESPEN\",\"volume\":\"64 \",\"pages\":\"Pages 425-434\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical nutrition ESPEN\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405457724015055\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition ESPEN","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405457724015055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

摘要

背景：帕金森病（PD）患者的食欲失调似乎与身体和认知能力的退化有关。研究人员将有认知障碍（CI）和无认知障碍（CI）的帕金森病患者与年龄匹配的对照组进行比较，以探索空腹和餐后食欲控制的预测因素：招募了55名患者并将其分为三组：20名对照组（年龄：74岁，体重指数：25.8kg/m2）、19名无认知障碍的帕金森病患者（年龄：72.5岁，体重指数：25.1kg/m2）和16名有认知障碍的帕金森病患者（年龄：74.3岁，体重指数：24.0kg/m2）。在空腹和餐后三小时内测量了自我报告的食欲感知和循环血液代谢生物标志物。生物标志物包括葡萄糖、胰岛素、肿瘤坏死因子α（TNF-α）、瘦素、酰基胃泌素、总胃泌素、肽YY（PYY）、胰高血糖素样肽1（GLP-1）、胰岛素生长因子1（IGF-1）、生长因子（GF）和甘油三酯。然后让患者自由进食混合餐，目的是评估代谢生物标志物与控制能量摄入之间的联系：结果：与对照组（21.9±3.1克）和无CI的PD患者（14.3±3.0克）相比，有CI的PD患者蛋白质摄入量明显较低（7.4±2.5克，P=0.01）。餐后血浆 GLP-1 浓度与饥饿感降低有关（B±SE，-5.3±2.4mm-h-1，p=0.04）。PYY浓度与空腹（r=0.40，p=0.005）和餐后（r=0.46，pConclusions：PYY和GLP-1似乎会影响帕金森病患者的食欲控制，它们的作用值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metabolic biomarkers of appetite control in Parkinson's disease patients with and without cognitive impairment

Background

Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions.

Methods

Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m²), nineteen PD patients without CI (72.5 y, 25.1 kg/m²) and sixteen PD patients with CI (74.3 y, 24.0 kg/m²). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat ad libitum with the aim to evaluate links between metabolic biomarkers and control of energy intake.

Results

PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, −5.3 ± 2.4 mm·h⁻¹, p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of ad libitum energy intake in all subjects (B±SE, −87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, −106.8 ± 44.9 kcal, p = 0.04).

Conclusions

PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical nutrition ESPEN NUTRITION & DIETETICS-

CiteScore

4.90

自引率

3.30%

发文量

512

期刊介绍： Clinical Nutrition ESPEN is an electronic-only journal and is an official publication of the European Society for Clinical Nutrition and Metabolism (ESPEN). Nutrition and nutritional care have gained wide clinical and scientific interest during the past decades. The increasing knowledge of metabolic disturbances and nutritional assessment in chronic and acute diseases has stimulated rapid advances in design, development and clinical application of nutritional support. The aims of ESPEN are to encourage the rapid diffusion of knowledge and its application in the field of clinical nutrition and metabolism. Published bimonthly, Clinical Nutrition ESPEN focuses on publishing articles on the relationship between nutrition and disease in the setting of basic science and clinical practice. Clinical Nutrition ESPEN is available to all members of ESPEN and to all subscribers of Clinical Nutrition.